Cui Xiao-Bin, Peng Hao, Li Su, Li Ting-Ting, Liu Chun-Xia, Zhang Shu-Mao, Jin Ting-Ting, Hu Jian-Ming, Jiang Jin-Fang, Liang Wei-Hua, Li Na, Li Li, Chen Yun-Zhao, Li Feng
Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China E-mail :
Asian Pac J Cancer Prev. 2014;15(22):9661-6. doi: 10.7314/apjcp.2014.15.22.9661.
A number of studies have identified a shared susceptibility locus in phospholipase C epsilon 1 (PLCE1) for esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinomas (GCA). However, the results of PLCE1 expression in esophageal and gastric cancer remain inconsistent and controversial. Moreover, the effects on clinicopathological features remain undetermined. This study aimed to provide a precise quantification of the association between PLCE1 expression and the risk of ESCC and GCA through meta-analysis.
Eligible studies were identified from PubMed, Wanfang Data, ISI Web of Science, and the Chinese National Knowledge Infrastructure databases. Using RevMan5.2 software, pooled odds ratios (ORs) with 95% confidence intervals (CIs) were employed to assess the association of PLCE1 expression with clinicopathological features relative to ESCC or GCA.
Seven articles were identified, including 761 esophageal and gastric cancer cases and 457 controls. Overall, we determined that PLCE1 expression was associated with tumor progression in both esophageal cancers (pooled OR=5.93; 95%CI=3.86 to 9.11) and gastric cancers (pooled OR=9.73; 95%CI=6.46 to 14.7). Moreover, invasion depth (pooled OR=3.62; 95%CI=2.30 to 5.70) and lymph node metastasis (pooled OR=4.21; 95%CI=2.69 to 6.59) were linked with PLCE1 expression in gastric cancer. However, no significant associations were determined between PLCE1 overexpression and the histologic grade, invasion depth, and lymph node metastasis in esophageal cancer.
Our meta- analysis results indicated that upregulated PLCE1 is significantly associated with an increased risk of tumor progression in ESCC and GCA. Therefore, PLCE1 expression can be appropriately regarded as a promising biomarker for ESCC and GCA patients.
多项研究已确定磷脂酶Cε1（PLCE1）中的一个共享易感基因座与食管鳞状细胞癌（ESCC）和贲门腺癌（GCA）相关。然而，PLCE1在食管癌和胃癌中的表达结果仍不一致且存在争议。此外，其对临床病理特征的影响仍未确定。本研究旨在通过荟萃分析精确量化PLCE1表达与ESCC和GCA风险之间的关联。
从PubMed、万方数据、ISI科学网和中国知网数据库中识别符合条件的研究。使用RevMan5.2软件，采用合并比值比（OR）和95%置信区间（CI）来评估PLCE1表达与ESCC或GCA临床病理特征之间的关联。
共纳入7篇文章，包括761例食管癌和胃癌病例以及457例对照。总体而言，我们确定PLCE1表达与食管癌（合并OR = 5.93；95%CI = 3.86至9.11）和胃癌（合并OR = 9.73；95%CI = 6.46至14.7）的肿瘤进展均相关。此外，胃癌的浸润深度（合并OR = 3.62；95%CI = 2.30至5.70）和淋巴结转移（合并OR = 4.21；95%CI = 2.69至6.59）与PLCE1表达有关。然而，在食管癌中，未确定PLCE1过表达与组织学分级、浸润深度和淋巴结转移之间存在显著关联。
我们的荟萃分析结果表明，PLCE1上调与ESCC和GCA肿瘤进展风险增加显著相关。因此，PLCE1表达可被适当视为ESCC和GCA患者有前景的生物标志物。
